Tales from the Trenches: Paul Edick, CEO of Xeris
After a remarkable career in biopharma, Paul Edick was enjoying retirement. Then he got the call to become CEO of Xeris Pharmaceuticals.
Drawn to the organization’s technology and mission, Paul agreed to take Xeris’ helm in 2017. With Xeris, Paul has again achieved remarkable success: Since 2017, Xeris has raised over $200M in capital (including taking the company public); completed several preclinical and clinical studies; established new corporate headquarters in downtown Chicago; built a state-of-the-art lab in San Diego and grown its staff to over 100 employees.
This summer, the company will commercialize its first product, which delivers the life-saving hormone glucagon to people with diabetes who experience a severe sudden drop in blood sugar.
Xeris is the latest in a long list of healthcare organizations that have achieved success under Paul's leadership. His impressive track record includes multiple biopharma startups, like Durata Therapeutics (Nasdaq: DRTX), with major acquisitions and IPOs.
Join us at the next event in our Tales from the Trenches™ series for lessons learned from Paul’s long career in biopharma and to hear about his unique journey from entrepreneurship to retirement — and back again. Jeffrey Aronin, MATTER co-founder, board member and CEO of Paragon Biosciences, will interview Paul.
5:30–6:00 | Networking
6:00–7:00 | Program (livestream available)
Tales from the Trenches is produced in partnership with Paragon Biosciences and Jumpstart Ventures.